

# Betting Against Beta

11/3/2025

---

## **Ute Capital**

---

Torlif Wegener

Garrett Pusey

Ryan O'Connor

Imran Al Sabbagh



# Executive Summary



## Strategy

Low beta stocks are underbought by retail & institutional investors; Buying low-beta stocks may lead to better risk-adjusted returns because these stocks tend to be undervalued.



## Performance

Over 10 years: 273.1% cumulative return, 0.78 Sharpe Ratio, Beta of 0.82, 32.7% 10 Y average turnover Slightly underperformed the S&P(314.7%).



## Recommendation

**Do Not Buy** Low Beta Strategy

# Strategy Rational

**Article Title:** [[“Betting against Beta”](#)]

## Key Takeaways:

- Investor constraints push capital into high-beta “lottery” stocks, causing them to become crowded and overpriced.
- Low-beta stocks are often under-owned and undervalued because investors can’t lever them to achieve desired returns.
- As a result, low-beta stocks tend to deliver steadier performance and higher risk-adjusted returns over time.

## Betting against beta<sup>☆</sup>

Andrea Frazzini<sup>a</sup>, Lasse Heje Pedersen<sup>a,b,c,d,e,\*</sup>

<sup>a</sup> AQR Capital Management, CT 06830, USA

<sup>b</sup> Stern School of Business, New York University, 44 West Fourth Street, Suite 9-190, NY 10012, USA

<sup>c</sup> Copenhagen Business School, 2000 Frederiksberg, Denmark

<sup>d</sup> Center for Economic Policy Research (CEPR), London, UK

<sup>e</sup> National Bureau of Economic Research (NBER), MA, USA

# Strategy Design

## Description

- Investors with shorting & leverage restrictions target high beta stocks to compensate; if we can identify securities overlooked by these investors, we can generate superior risk-adjusted returns

## Origin

- The paper was found in The Journal of Financial Economics

## Goal

- If we purchase companies with low betas, then we will realize better risk-adjusted returns, because these stocks are often undervalued

## Parameters

- Worked to eliminate microcap stocks, modest beta, high free float, limited debt, and sustained EPS growth

# Back testing Parameters

## Screening Criteria

Parameter	Description	Stock Universe
Market Cap	>\$300M	3,417 stocks
Beta	0.8 <= Beta <= 1	717 stocks
Free Float %	95%	344 stocks
Net Debt to Shareholder Equity	<= 20%	132 stocks
T12M Diluted Earnings Per Share	>= 5	32 stocks
Current Price to Earnings Ratio	<= 30	26 stocks
Top 15 Rank Return on Common Equity	N/A	15 stocks

# Monte Carlo Simulation

## Simulation Model Configuration

Portfolio Type 	Tickers 
Initial Amount 	50000 
Cashflows 	No contributions or withdrawals 
Simulation Period in Years 	30 
Tax Treatment 	Pre-tax Returns 
Simulation Model 	Historical Returns 
Use Full History 	Yes 
Bootstrap Model 	Single Year 
Sequence of Returns Risk 	No Adjustments 
Inflation Model 	Historical Inflation 
Rebalancing 	Rebalance quarterly 
Intervals 	Defaults 

# Expected Returns

## Expected Annual Return

Percentile	1 Year	3 Years	5 Years	10 Years	15 Years	20 Years	25 Years	30 Years
10th Percentile	-4.05%	3.50%	5.93%	8.25%	9.31%	9.95%	10.42%	10.74%
25th Percentile	-0.85%	8.10%	9.59%	10.94%	11.61%	11.96%	12.19%	12.31%
50th Percentile	13.72%	14.38%	14.12%	14.13%	14.12%	14.13%	14.13%	14.10%
75th Percentile	30.66%	20.00%	18.64%	17.32%	16.65%	16.36%	16.12%	15.92%
90th Percentile	33.81%	26.03%	22.97%	20.18%	19.00%	18.35%	17.84%	17.52%

# Expected Losses

## Loss Probabilities

Loss	Within Time Period	End of Time Period
>= 2.50%	62.44%	0.00%
>= 5.00%	40.62%	0.00%
>= 7.50%	33.32%	0.00%
>= 10.00%	30.44%	0.00%
>= 12.50%	27.28%	0.00%
>= 15.00%	26.38%	0.00%
>= 17.50%	18.46%	0.00%
>= 20.00%	14.69%	0.00%
>= 22.50%	13.96%	0.00%
>= 25.00%	13.25%	0.00%
>= 27.50%	12.98%	0.00%
>= 30.00%	2.65%	0.00%
>= 32.50%	0.70%	0.00%
>= 35.00%	0.35%	0.00%
>= 37.50%	0.16%	0.00%
>= 40.00%	0.06%	0.00%

Loss is measured against the original portfolio balance.

# Back testing Results – Performance



Period	Return	$\alpha$	$\beta$	$\sigma$	Max DD	Sharpe
1yr	10.5%	-4.1	0.8	18.98	3.9%	0.44
1yr SPX	17.6%	0	1	11.23	5.2%	1
10yr	273.1%	1.35	0.82	17.69	-24.1%	0.78
10yr SPX	314.7%	0	1	15.29	-24.1%	0.72

# Back testing Results – Performance




Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Mean
<b>STRAT</b>	2.5%	10.6%	28.4%	1.7%	19.3%	16.7%	35.9%	-13.3%	30.5%	9.0%	8.4%	13.6%
<b>S&amp;P</b>	8.0%	10.9%	21.8%	-5.2%	32.2%	18.0%	29.9%	-18.3%	26.3%	25.5%	14.4%	14.9%

# Recommended Purchases



Name	Ticker	P/E Ratio	Monthly Trading Volume (\$M)	Market Cap (\$B)	Share Price	# of Shares	Total Value
Automatic Data Processing	ADP	23.86	0.807	\$118.9	\$260.30	12	\$3,123.60
Bank of New York	BK	14.61	0.359	\$76.8	\$107.93	29	\$3,129.97
EOG Resources	EOG	10.56	0.579	\$61.2	\$105.84	32	\$3,386.88
Paccar Inc.	PCAR	19.23	0.870	\$51.6	\$98.40	34	\$3,345.60
Resmed Inc.	RMD	22.64	0.270	\$40.1	\$246.88	13	\$3,209.44
Cincinnati Financial Corp.	CINF	21.76	0.455	\$24.7	\$154.59	22	\$3,400.98
Snap-On Inc.	SNA	17.56	0.020	\$18.1	\$335.55	10	\$3,355.50
Expeditors International	EXPD	22.14	0.126	\$16.6	\$121.90	27	\$3,291.30
Houlihan Lokey Inc.	HLI	22.77	0.238	\$14.4	\$179.08	19	\$3,402.52
AtkinsRealis Group Inc.	SNCAF	6.77	0.100	\$11.9	\$70.67	47	\$3,321.49
InterDigital Inc.	IDCC	24.21	0.136	\$8.9	\$361.96	9	\$3,257.64
Essent Group	ESNT	8.49	0.060	\$6.3	\$60.57	55	\$3,331.35
Plexus Corp	PLXS	18.71	0.063	\$3.9	\$139.90	24	\$3,357.60
Lindsay Corp	LNN	18.40	0.009	\$1.5	\$111.24	30	\$3,337.20
QCR Holdings	QCRH	10.08	26,643	\$1.3	\$74.39	45	\$3,347.55

# Effect on the Portfolio


## Proposed Investment Sectors



## Current Portfolio



## New Portfolio



Portfolio	Exp. Return	St. Dev	Beta	Sharpe Ratio	Idio. Risk	Info. Ratio
Existing	19.00%	6.78%	0.79	-0.40	8.47%	-3.62
Adjusted						

# Risks

“Betting against Beta” is primarily a hedge strategy that includes long on low beta stocks and shorts on high beta stocks, which ultimately was not possible within MSIF.

<b><u>Risk Category</u></b>	<b>Specific Risks</b>	<b>Mitigations</b>
<b>Model &amp; Research</b>	Difficult to form firm thesis from literature in a way that fits our fund	Collaborative approach to criteria definition
<b>Data &amp; Assumptions</b>	Strategy was not fully replicable	Raised beta parameters
<b>Portfolio</b>	Saw deviation from large-cap low beta value stocks to medium-cap, higher volatility stocks in recent rebalances	Adjust diluted EPS growth and Debt to Equity

# Summary & Recommendation

## Strategy Merits



- **Performance**

Underperformed S&P with more risk, lower alpha; not attractive in the current market environment.



- **Risk**

Strong downside protection, but upside is too limited in a risk-on environment



- **Effects on Portfolio**

Would reduce fund beta and constrain upside; not aligned with fund objectives

## Action Plan



- **Recommendation: Not to invest in this strategy**